Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone [Yahoo! Finance]
Biodexa Pharmaceuticals plc - American Depositary Shares (BDRX)
Company Research
Source: Yahoo! Finance
Safety profile established in more than 700 patients CARDIFF, UK / ACCESSWIRE / March 1, 2024 / While type 2 diabetes is frequently discussed in the media, the 1.3 million U.S. adults who struggle with type 1 diabetes are sometimes forgotten about. Type 1 diabetes is a chronic autoimmune condition in which the body's immune system attacks and destroys the insulin-producing cells in the pancreas. This leads to a deficiency of insulin, a hormone necessary for regulating blood sugar levels. People with type 1 diabetes require lifelong insulin therapy to manage their blood sugar and avoid complications. Without proper treatment, type 1 diabetes is a life-threatening condition. Clinical-stage biopharmaceutical company Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) is looking to improve treatment options for individuals with type 1 diabetes. Recent data has shown that the prevalence of type 1 diabetes is increasing annually by 0.34% , with approximately 500,000 global cases per year. The
Show less
Read more
Impact Snapshot
Event Time:
BDRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BDRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BDRX alerts
High impacting Biodexa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BDRX
News
- Posting of Annual Report & Notice of AGM - Total Voting Rights [Yahoo! Finance]Yahoo! Finance
- Posting of Annual Report & Notice of AGM - Total Voting RightsGlobeNewswire
- Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition [Yahoo! Finance]Yahoo! Finance
- Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous ConditionAccesswire
- Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting [Yahoo! Finance]Yahoo! Finance
BDRX
Sec Filings
- 5/15/24 - Form 6-K
- 5/15/24 - Form 6-K
- 5/3/24 - Form 424B3
- BDRX's page on the SEC website